Yiying Wang

Cooley advised Akeso (Hong Kong Stock Exchange: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$3.97 billion (US$509.01 million) placement of shares.

Cooley advised Nanjing Leads Biolabs Co. (Leads Biolabs), a clinical-stage biotechnology company that discovers, develops and commercializes new therapies in oncology, autoimmune and other severe diseases, on its HK$1.29 billion initial public offering (IPO).

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Cooley advised the sponsors and underwriters of Jiangsu Zenergy Battery Technologies Group (Zenergy) – a lithium-ion battery manufacturer focusing on the research and development, production and sales of electric vehicle battery products, electrochemical energy storage battery products and aviation battery products – in connection with Zenergy’s HK$1 billion global initial public offering.

Cooley advised the sponsors and underwriters of BrainAurora Medical Technology, a provider of medical diagnostics and digital therapies, in connection with the company’s HK$583 million initial public offering.